Source: Aastocks.com

How does Noah Medical build a sustainable business loop?

This is the fourth in a series of in-depth studies on Noah Medical, aiming to dissect the company's value realization path from a business model perspective.

In the first three weeks of our series of studies, we established a value judgment framework for the medical robotics industry, dissected the clinical challenges of the 'diagnostic capability gap' and the lack of 'non-invasive integrated diagnosis and treatment' in the early diagnosis of lung cancer, and analyzed the technical solutions built by Noah Medical around the two core capabilities of 'arrival + real-time positioning'.

This naturally raises a key question: After solving clinical problems, how can this technological capability be transformed into sustainable commercial value?

For a successful medical robotics company, technical expertise is a necessary but not sufficient condition. What the capital market truly cares about is whether a company can translate clinical value into a predictable, repeatable, and scalable revenue model. This article will analyze Noah Medical's business logic from four dimensions: revenue structure, product design, policy environment, and platform expansion.

I. Equipment is just the entry point; consumables are the core.

The key to understanding Noah Medical's business model lies in breaking the stereotype that "medical robots = equipment sales".

In the traditional medical device industry, revenue is typically driven primarily by equipment sales, with the installation pace having a significant impact on performance. Although some areas have gradually incorporated recurring revenue from maintenance and upgrades, their overall proportion remains relatively limited. Truly successful companies, however, typically build a growth flywheel driven by repeat purchases—using equipment as the entry point, and consumables and services as the source of continuous revenue.

Noah Medical's business model is a typical example of the latter. The company has built a three-tiered revenue structure around the Galaxy system: "main unit + disposable bronchoscope + services".

Income levels, product forms, and income characteristics

The Galaxy main unit system generates revenue from one-time installations , establishes a clinical entry point, and facilitates repurchases every 5-7 years.

The consumables layer includes disposable robotic bronchoscopes and accessories, which are required for each surgery and can be repurchased for each patient.

After one year of service layer maintenance, software upgrades, and training equipment installation, sales volume gradually increases, with annual repurchases.

In this structure, disposable consumables are the core engine driving revenue growth. Unlike traditional reusable bronchoscopes, the Galaxy system's disposable design means that each surgery will use a completely new robotic bronchoscope and its accessories. As the number of devices installed increases and doctors become more proficient in using them, consumable revenue will show non-linear growth—this is the underlying logic of the 'flywheel effect'.

Commercial data from the US market shows that this model has entered the validation phase. Since its FDA approval in 2023, the Galaxy system has completed over 10,000 surgeries, with more than 50 units installed. Based on the consumable consumption per surgery, the annual consumable revenue per unit has reached a measurable and stable baseline, and the robot's usage rate will continue to rise as doctors' proficiency increases and the indications expand.

II. AI-driven product design is the underlying support for the large-scale production of consumables.

Whether a consumables-driven business model can succeed depends on a crucial premise: whether the equipment will actually be used frequently. If the robot's clinical value is not significant, the system operation is complex, the learning curve is steep, and the clinical efficiency is low, the phenomenon of "silent devices" after installation will be inevitable, and the volume of consumables will be out of the question. This is precisely the real dilemma faced by many medical robot companies; simply lowering the price of the robot's main unit cannot bring about long-term sustainable growth.

Noah Medical's differentiation lies in the fact that its Galaxy system integrates AI capabilities from the ground up, giving the product a natural ability to be continuously used and to learn from the surgery itself through AI. This capability permeates the entire surgical process:

In the path planning stage, the AI ​​algorithm automatically completes airway segmentation and path planning based on preoperative CT images, greatly reducing and simplifying the work that originally required doctors to do manually, and significantly lowering the threshold for preoperative preparation.

Lesion identification: The system's built-in AI image analysis capabilities can help identify tiny lesions in the peripheral lung region, reducing doctors' workload and enabling more accurate real-time localization.

Real-time localization: 3D Imaging (DT) technology uses AI-driven tomographic synthesis algorithms to reconstruct three-dimensional images in real time from intraoperative C-arm images, dynamically correcting deviations between CT images and the patient's actual anatomy. This capability directly solves the core clinical problem of "CT-to-body divergence," which has plagued clinicians for many years.

Results confirmation stage: Enhanced fluoroscopy and StrikePoint™ technology use AI algorithms to overlay the lesion location onto the 2D fluoroscopic image in real time, enabling doctors to "see" lesions that are not visible to the naked eye, and to accurately measure the relative distance between the tool and the lesion in 3D space.

The deep integration of AI brings not only performance improvements but also a systematic reduction in the barrier to entry. Traditional bronchoscopic biopsy of peripheral lung nodules requires a high level of physician experience, with a learning curve that can take years. The Galaxy system, however, standardizes and visualizes this process, reducing the learning time for doctors to just a few hours. The commercial implications of this shift are that the installed equipment will not remain idle because "only a few experts can use it," but will be quickly integrated into daily clinical workflows, enabling ordinary or young doctors to rapidly become excellent physicians with the support of robots and AI, driving a continuous increase in surgical volume and consumable consumption.

III. Favorable Policy: Payment Window Opens Simultaneously in Both Chinese and American Markets

The "last mile" of commercializing any medical innovation is also a crucial link, and that's payment. No matter how good the technology and product are, without a clear charging path and payment incentives, large-scale scaling is out of the question.

At this juncture, Noah Medical is facing a situation where the payment windows in the two major markets of China and the United States are opening almost simultaneously—a situation rarely seen in the narrative of globalization of medical technology.

The technological foundation of this approach lies in the deep integration of real-time image localization and AI with robotic control systems. The Galaxy system can dynamically correct the deviation between the image and the human body during surgery, achieving higher-precision real-time lesion localization in complex environments—which is precisely the key technical challenge in the current diagnosis of peripheral pulmonary nodules.

US Market: TPT Payments Provide Direct Economic Incentives

Starting in January 2024, the Centers for Medicare & Medicaid Services (CMS) established a Transitional Pathway Payment (TPT) code for eligible single-use bronchoscopes. This means that medical institutions using Galaxy single-use bronchoscopes can receive an additional reimbursement of approximately $2,000 on top of the standard surgical fee. This policy has a two-way impact on the business model: on the one hand, the additional reimbursement directly improves the economic model of hospitals per surgery, lowering the barrier to equipment use; on the other hand, TPT payment only applies to single-use bronchoscopes, and reusable products are not eligible—this essentially constitutes a policy endorsement of Noah Medical's business model.

In addition to the additional TPT (Total Physical Expense) reimbursement, robotic bronchoscopes have had mature insurance reimbursement for many years. The combination of these two reimbursements allows Galaxy's disposable robotic bronchoscope solution to bring substantial financial returns to hospitals.

China Market: Pricing Paths Becoming Clearer

In the Chinese market, the commercial payment environment has also seen a key breakthrough. The National Healthcare Security Administration's "Guidelines for the Establishment of Medical Service Pricing Items for Surgical and Treatment Assistance" explicitly includes "robotic arm-assisted operation" and its dedicated consumables in the medical service pricing items nationwide.

The significance of this policy lies in the fact that the pricing for robot-assisted surgery and related consumables has moved from a "gray area" into a "compliant framework." For Noah Medical (a wholly-owned subsidiary of Noah Medical in the United States), which is about to launch its commercialization in China, this has cleared a key obstacle to its commercialization.

At the same time, its domestic production status also gives the Pribaichuan system (Galaxy China version) a potential advantage in pricing and market access. Compared to imported competitors, domestic products usually enjoy greater flexibility in medical insurance access negotiations and hospital bidding and procurement, which provides a more favorable market environment for the subsequent volume expansion of consumables.

IV. From Diagnosis to Treatment – ​​“Integrated Diagnosis and Treatment”: The “Value Depth” of a Single Device

A good business model requires not only horizontal expansion of installed capacity, but also vertical exploration of the value of each individual device.

The commercialization path of the Galaxy system is extending from 'diagnosis' to 'integrated diagnosis and treatment'. In the traditional lung cancer diagnosis and treatment process, diagnosis and treatment are two separate steps—patients first undergo a biopsy for diagnosis, and then undergo elective surgery. This not only increases the patient's waiting time and psychological burden, but also objectively leads to multiple consumptions of medical resources.

The Galaxy system's "arrival + real-time positioning" capabilities make "diagnosis as treatment" possible. After accurately reaching the lesion and confirming it with a biopsy, doctors can directly perform ablation, local drug delivery, and local radiotherapy through the same system and channel. Patients do not need a second surgery, realizing a treatment model of "one anesthesia, one surgery, diagnosis and treatment."

The commercial value of this extension lies in the potential for a continuously enriched structure of consumables used per surgery, driving up revenue per case. Currently based on consumables related to robot navigation and positioning (such as disposable robotic bronchoscopes), as the platform's capabilities expand, it is expected to gradually introduce diagnostic and therapeutic consumables (such as biopsy needles and intelligent ablation tools) in the future, provided compliance is ensured. Furthermore, through cooperation with industry chain partners, the long-term and sustainable revenue potential per device can be further expanded.

In the longer term, the capabilities of the Galaxy system continue to expand. In the field of lung cancer, the system is extending from peripheral nodule biopsy to lymph node staging and radical treatment of early-stage lung cancer. Each new entry point means a new clinical scenario and a new category of consumables—the "value depth" of a single device will continue to increase accordingly.

V. Platform-based expansion: The long-term value development potential of the business model

If lung cancer diagnosis laid the foundation for Noah Medical's business model, then extending along natural cavities to multiple departments is expected to form a growth engine with the ability to be replicated across different scenarios.

From a technical perspective, the core capabilities of the Galaxy system—flexible robot control, real-time image fusion, AI-assisted navigation, and disposable flexible endoscopes—are not designed for a single department. Multiple natural cavity systems in the human body (non-invasive interventional diagnosis, treatment, and surgery) share highly similar interventional pathways, meaning that the same technological system has the foundation for cross-departmental reuse.

The company's pipeline layout has initially validated this logic. In addition to the lung cancer biopsy platform, next-generation systems for early tumor diagnosis and treatment in other departments have entered different stages of development.

From a business perspective, platform expansion has dual value:

First, there is an advantage in R&D efficiency. The cross-departmental reuse of core technologies and system architectures means that the marginal cost of developing new indications decreases. Compared to single-product companies that "start from scratch," platform companies have a significantly higher return on R&D investment.

Secondly, we delve deeper into customer value. Within the same hospital client group, we expand from single-department penetration to multi-department coverage, which not only increases the revenue contribution from each client but also strengthens customer loyalty.

This development path of "single-point entry → platform expansion" is highly similar to the development trajectory of benchmark companies in the surgical robot industry. From single surgical procedures to multi-department coverage, from equipment sales to consumables + service-driven growth, each step of expansion corresponds to a leap in valuation logic.

Conclusion

For medical technology companies in the early stages of commercialization, the capital market typically undergoes a cognitive shift—from "using technology to solve clinical problems" to "business closed loop and continuous growth."

The first three weeks of research answered the question of "using technology to solve clinical problems": Noah Medical addressed a real clinical capability gap and built a targeted technological solution. This article, however, attempts to answer the question of "business loop and sustainable growth": Does the company have the ability to convert clinical value into sustainable revenue?

The answer is clear and verifiable. The revenue model of "equipment + consumables + services" has been initially validated in the US market. AI-driven product design ensures the high-frequency use of the equipment, payment policies in both the US and Chinese markets provide a favorable environment for commercialization, and the potential for integrated diagnosis and treatment and multi-departmental expansion opens up space for long-term growth.

For institutional investors, such targets often share a common characteristic: their technological capabilities and business models are not separate entities, but rather an organic whole that interlocks and reinforces each other. The AI ​​capabilities of the Galaxy system lowered the barrier to entry and drove increased sales of consumables; the design of disposable robotic bronchoscopes improved clinical efficiency and optimized the revenue model; and the platform architecture enhanced R&D efficiency and raised the valuation ceiling.

When the technology story and the business story begin to corroborate each other, the long-term value profile of a company gradually becomes clear.

— This is the fourth installment in Noah Medical's in-depth research series —

This article was originally published on Aastocks.com and is reprinted with permission from Tianjin Puli Ark Medical Technology Co., Ltd. Copyright belongs to the original author. Please contact the original source for reprint permission. This article does not constitute medical advice; please consult your doctor for specific diagnosis and treatment.

Disclaimer: The content on this platform is for academic exchange among medical professionals only and does not constitute any medical advice. Patients with medical needs should consult a doctor for professional guidance. The technical opinions of medical professionals published on this platform do not represent the position of this company.

Copyright of all content in this article belongs to Puli Ark. Unauthorized reproduction or adaptation in any form is prohibited. Our company assumes no responsibility for any losses caused by improper reproduction or citation of this article and reserves the right to pursue legal action against infringers.